Table 2.

The summary performance of diagnostic estimates.

Genes	Study-Case/Control	SEN (95% CI)	SPE (95% CI)	PLR (95% CI)	NLR (95% CI)	DOR (95% CI)
CDH1	1–26/33	0.35 (0.17–0.56)	0.70 (0.51–0.84)	1.14 (0.55–2.39)	0.94 (0.66–1.00)	1.22 (0.41–3.65)
SOX17	1–90/24	0.84 (0.75–0.91	0.88 (0.68–0.97)	6.76 (2.34–19.54)	0.18 (0.11–0.29)	38.00 (9.98–144.73)
CDO1	1–90/24	0.78 (0.68–0.86)	0.67 (0.45–0.84)	2.32 (1.31–4.15)	0.33 (0.21–0.54)	7.00 (2.62–18.72)
ZFP42	1–90/24	0.87 (0.78–0.93)	0.63 (0.41–0.81)	2.31 (1.37–3.90)	0.21 (0.12–0.39)	10.83 (3.88–30.22
TAC1	1–90/24	0.86 (0.77–0.92)	0.75 (0.53–0.90)	3.42 (1.70–6.88)	0.19 (0.11–0.33)	17.77 (5.94–53.12)
H-cadherin	1–53/118	0.50 (0.23–0.77)	0.57 (0.46–0.68)	1.18 (0.66–2.11)	0.87 (0.50–1.00)	1.35 (0.43–4.22)
FHIT	2–126/46	0.52 (0.43–0.61)	0.91 (0.79–0.98)	5.93 (2.29–15.36)	0.53 (0.43–0.65)	11.19 (3.79–33.06)
PCDH20	2–104/154	0.58 (0.48–0.67)	0.49 (0.41–0.58)	1.14 (0.91–1.43)	0.86 (0.65–1.00)	1.33 (0.80–2.19)
Dab2	2–104/154	0.03 (0.01–0.08)	0.99 (0.95–1.00)	2.22 (0.38–13.06)	0.98 (0.95–1.00)	2.26 (0.37–13.75)
Dcr2	2–104/154	0.41 (0.32–0.51)	0.60 (0.52–0.68)	1.03 (0.76–1.38)	0.98 (0.80–1.00)	1.05 (0.63–1.73)
SULF2	2–104/154	0.51 (0.41–0.61)	0.57 (0.49–0.65)	1.19 (0.91–1.55)	0.86 (0.68–1.00)	1.39 (0.84–2.28)
Kifla	2–104/154	0.44 (0.34–0.54	0.62 (0.54–0.70	1.17 (0.87–1.58)	0.89 (0.72–1.00)	1.31 (0.79–2.18)
Dal-1	2–104/154	0.30 (0.21–0.39	0.86 (0.80–0.91	2.17 (1.32–3.55)	0.82 (0.71–0.94)	2.65 (1.42–4.94)
Jph3	2–104/154	0.31 (0.23–0.41	0.79 (0.721–0.85	1.47 (0.97–2.22)	0.87 (0.75–1.00)	1.68 (0.96–2.95)
RASSF2	2–104/154	0.08 (0.03–0.15)	0.95 (0.91–0.98)	1.69 (0.63–4.52)	0.97 (0.91–1.00)	1.75 (0.61–4.98)
TCF2l	2–104/154	0.29 (0.20–0.39)	0.71 (0.63–0.78)	0.99 (0.67–1.46)	1.01 (0.86–1.00)	0.98 (0.57–1.70)
CXCL	2–80/180	0.36 (0.26–0.48	0.79 (0.72–0.85	1.72 (1.15–2.58)	0.81 (0.67–0.97)	2.12 (1.19–23.79)
MAGE	4–202/118	0.45 (0.34–0.55	0.82 (0.56–0.94	2.44 (0.75–7.96	0.68 (0.47–0.99	3.60 (0.76–16.98
HOXA	4–276/174	0.79 (0.63–0.89)	0.50 (0.16–0.84)	1.56 (0.80–3.07)	0.43 (0.28–0.66)	3.63 (1.28–10.26)
RARβ	4–257/223	0.44 (0.29–0.60)	0.79 (0.58–0.91)	2.09 (0.93–4.70)	0.71 (0.52–0.98)	2.93 (0.99–8.69)
FAM19A4	3–252/271	0.80 (0.74–0.85	0.25 (0.20–0.30)	1.06 (0.97–1.16)	0.82 (0.59–1.00)	1.29 (0.86–1.96)
PHACTR3	3–252/271	0.60 (0.53–0.66	0.68 (0.62–0.73)	1.85 (1.52–2.27)	0.60 (0.50–0.71)	3.11 (2.17–4.45)
DAPK	5–337/389	0.45 (0.40–0.51)	0.79 (0.64–0.89)	2.16 (1.13–4.14)	0.69 (0.58–0.86)	3.12 (1.32–7.36)
3OST2	4–369/445	0.50 (0.45–0.55)	0.85 (0.82–0.88)	3.36 (2.63–4.30)	0.59 (0.53–0.66)	5.71 (4.10–7.96)
PRDM14	4–369/445	0.62 (0.57–0.67)	0.76 (0.72–0.80)	2.63 (2.19–3.17)	0.50 (0.43–0.57)	5.30 (3.91–7.17)
GATA	6–404/492	0.66 (0.31–0.90)	0.53 (0.33–0.71)	1.40 (1.16–1.69)	0.64 (0.34–1.21)	2.20 (1.01–4.83)
MGMT	8–447/460	0.42 (0.32–0.52)	0.91 (0.77–0.97)	4.78 (1.47–15.55)	0.64 (0.50–0.81)	7.48 (1.87–29.91)
PAX5	8–510/728	0.37 (0.29–0.45)	0.78 (0.70–0.84)	1.65 (1.28–2.12)	0.81 (0.74–0.90)	2.02 (1.45–2.83)
CYGB	6–453/853	0.51 (0.45–0.57)	0.79 (0.69–0.88)	2.39 (1.61–3.56)	0.62 (0.54–0.72)	3.83 (2.28–6.44)
APC	8–588/928	0.43 (0.34–0.53)	0.87 (0.71–0.95)	3.30 (1.67–6.51)	0.65 (0.59–0.72)	5.06 (2.55–10.04)
p16	24–1357/1249	0.48 (0.40–0.56)	0.90 (0.82–0.95)	4.71 (2.53–8.78)	0.58 (0.50–0.68)	8.11 (3.94–16.70)
RASSF1A	17–1160/1767	0.28 (0.20–0.38)	0.95 (0.93–0.97)	5.61 (3.73–8.43)	0.76 (0.67–0.85)	7.40 (4.54–12.06)
Summary	33–2238/2563	0.46 (0.41–0.50)	0.83 (0.80–0.86)	2.72 (2.32–3.22)	0.64 (0.60–0.68)	4.28 (3.50–5.20)

DOR: Diagnostic odds ratio; NLR: Negative likelihood ratio; PLR: Positive likelihood ratio; SEN: Sensitivity; SPE: Specificity. Bold text: The top five values.